QURE

Uniqure NV

Add to Watchlist

Advanced Chart

13.800

+0.52(3.916%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

13.9455

Open

13.110

VWAP

13.37

Vol

512.96K

Mkt Cap

728.63M

Low

12.890

Amount

6.86M

EV/EBITDA(TTM)

Total Shares

48.55M

858.76M

EV/OCF(TTM)

P/S(TTM)

47.59

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

7.49M

+378.62%

-0.893

+9.08%

16.03M

+207.08%

-0.754

-49.72%

5.56M

+142.06%

-0.871

-4.58%

Estimates Revision

The market is revising Downward the revenue expectations for uniQure N.V. (QURE) for FY2025, with the revenue forecasts being adjusted by -3.32% over the past three months. During the same period, the stock price has changed by 4.94%.

Revenue Estimates for FY2025

Revise Downward

-3.32%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.86%

In Past 3 Month

Stock Price

Go Up

+4.94%

In Past 3 Month

10 Analyst Rating

193.99% Upside

Wall Street analysts forecast QURE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QURE is 40.57 USD with a low forecast of 24.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

193.99% Upside

Current: 13.800

Low

24.00

Averages

40.57

High

70.00

193.99% Upside

Current: 13.800

Low

24.00

Averages

40.57

High

70.00

Cantor Fitzgerald

Overweight

maintain

$58 -> $47

2025-07-30

Reason

Cantor Fitzgerald

Price Target

$58 -> $47

2025-07-30

maintain

Overweight

Reason

Cantor Fitzgerald lowered the firm's price target on uniQure to $47 from $58 and keeps an Overweight rating on the shares following the Q2 earnings report. The main update from the earnings call is that the statistical analysis plan for AMT-130 in Huntington's disease has been submitted, the analyst tells investors in a research note. Cantor thinks the September data could be a strong catalyst that could help to make the case that this therapy could be approved.

Mizuho

Neutral

maintain

2025-07-29

Reason

Mizuho

Price Target

2025-07-29

maintain

Neutral

Reason

Mizuho said the firm believes uniQure shares are down likely due to a few factors, though it believes these factors are ultimately \"non-issues.\" The analyst cited the switch from propensity score weighting to propensity score measurement, though management said this is a non-issue and even a positive as FDA preference and recommendation is for PSM; some concerns about a delay in three-year data reading out in September, and; at-the-market filing may add pressure. The firm has a Neutral rating on uniQure.

Chardan

Buy

downgrade

$38 -> $35

2025-07-29

Reason

Chardan

Price Target

$38 -> $35

2025-07-29

downgrade

Buy

Reason

Chardan lowered the firm's price target on uniQure to $35 from $38 and keeps a Buy rating on the shares after the company reported Q2 results. The company ended the quarter with cash and equivalents of $377M, supporting a projected operational runway into 2H27, the analyst tells investors in a research note. The firm also noted the company plans to present data in September from the ongoing Phase 1/2 studies of AMT-130 in support of a potential biologics license application submission, including three years of follow-up data for 24 treated patients.

H.C. Wainwright

Buy

maintain

$70

2025-05-29

Reason

H.C. Wainwright

Price Target

$70

2025-05-29

maintain

Buy

Reason

H.C. Wainwright reiterates a Buy rating on uniQure with a $70 price target after the company announced data from the first mesial temporal lobe epilepsy patient treated with AMT-260. These early data, while from only one patient, are encouraging, and support advancement of the program to additional patients with drug-refractory mTLE who have no available treatment options, the analyst tells investors in a research note. The firm believes that if AMT-260's early safety profile is confirmed in additional patients, uniQure may advance the program to the randomized Phase 2 portion of the trial in 2026.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$70

2025-04-21

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$70

2025-04-21

Reiterates

Strong Buy

Reason

Chardan Capital

Daniil Gataulin

Strong Buy

Maintains

$27 → $38

2025-04-01

Reason

Chardan Capital

Daniil Gataulin

Price Target

$27 → $38

2025-04-01

Maintains

Strong Buy

Reason

Chardan took over coverage of uniQure with a Buy rating and price target of $38. The analyst, who cites the potential of the company's AAV-based gene therapy pipeline to "uniquely address" unmet medical need in Huntington's disease, with additional upside potential in epilepsy, ALS, and Fabry disease, believes the shares offer a favorable risk-reward.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Uniqure NV (QURE.O) is -3.80, compared to its 5-year average forward P/E of -7.58. For a more detailed relative valuation and DCF analysis to assess Uniqure NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.58

Current PE

-3.80

Overvalued PE

9.50

Undervalued PE

-24.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.44

Current EV/EBITDA

-7.28

Overvalued EV/EBITDA

11.56

Undervalued EV/EBITDA

-18.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

13.14

Current PS

23.74

Overvalued PS

27.45

Undervalued PS

-1.16